Comorbidity mattered more than chronological age after proton therapy for hepatocellular carcinoma
Age ≥75 did not independently predict outcomes after proton therapy for HCC, while CCI ≥3 was associated with more than threefold higher mortality.
We read the journals so you don't have to.
A free weekly digest of the radiation oncology research that matters.
Free forever. One email a week. Unsubscribe anytime.
Latest
Aggressive concurrent hypofractionation increased fatal toxicity in unresectable stage II–III NSCLC
Across 26 studies, fatal toxicity clustered when BED10 >100 Gy was delivered to the whole tumor with concurrent platinum chemotherapy.
Cardiac dose patterns and early ECG changes differed by breast cancer laterality
Left-sided breast IMRT was linked to more repolarization changes, while right-sided treatment produced predominantly rhythm abnormalities.
Two-week PACTUS radiotherapy showed feasibility in frail patients with anal cancer
PACTUS 40 Gy/10 produced 30-month median survival in 28 selected frail patients, but incomplete response and toxicity data limit efficacy conclusions.
Deep learning could provide a second-check for prostate pelvic nodal contours
AI pelvic nodal contours achieved a Dice score of 0.79 on withheld prostate RT cases but retained localized boundary disagreements.
Heart-base optimization substantially reduced cardiac substructure dose in distal esophageal RT
Heart-base-optimized IMRT/VMAT reduced cardiac avoidance area mean dose by about 6 Gy without compromising target coverage.
Simulation-free VMAT preserved delivered dose for palliative bone radiotherapy
Diagnostic CT-based VMAT preserved PTV D95 at 99.6% of planned dose across 30 palliative bone RT plans.
Brachytherapy-integrated hyperthermia remains technically feasible but clinically unproven
Two randomized trials failed to show benefit from brachytherapy-integrated hyperthermia, while inadequate thermal measurement remains a major barrier to clinical validation.
Proton RBE rose sharply beyond the Bragg peak in pancreatic cancer cells
In two PDAC cell lines, measured proton RBE remained near 1.0 through the Bragg peak but rose as high as 6.1 distally.
Iridium-192 remains the best-supported HDR source for breast brachytherapy
Iridium-192 has the strongest long-term breast brachytherapy evidence; cobalt-60 is dosimetrically comparable, while ytterbium-169 remains clinically unvalidated.
Ultracentral lung SBRT produced more grade 3 toxicity than central SBRT
Grade 3 toxicity was 16.7% for ultracentral versus 8.7% for central lung tumors, with no grade ≥4 events in this real-world cohort.
Proton SBRT achieved 77% two-year local control in high-risk lung tumors
In a prospective proton registry enriched for ultracentral, large, and re-irradiated lung tumors, two-year local control was 77% with no grade ≥3 toxicity.
Metastasis-directed EBRT was feasible alongside Lu-PSMA-617 in metastatic prostate cancer
Among 88 patients receiving both treatments, PSA50 response was 55.7% and prior metastasis-directed EBRT did not increase hematologic toxicity.
Small photon fields reduced detected Cherenkov signal despite stable dose-linked production
Detected Cherenkov signal per dose fell sharply in small fields, driven mainly by optical transport rather than major changes in intrinsic Cherenkov production.
Integrated rapid palliative RT achieved fast treatment without a dedicated clinic
A routine departmental workflow delivered rapid palliative RT with a median 109-minute treatment process despite having no dedicated rapid-access clinic.